Monte Rosa Therapeutics, Inc. (GLUE) stock forecast and price target
Price $9.37 · data as of November 13, 2026
12-month price target
Average target$25.38
Upside / downside+170.8%
Analysts8
ConsensusStrong buy
Low $15.00Average $25.38High $37.00
Gold marker: average target · white marker: today’s price ($9.37)
Analyst ratings
Strong buy 2Buy 8Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.02 | −122.4% | $102M |
| Next fiscal year ends December 31, 2027 | $-1.78 | −73.6% | $62M |
| Next quarter ends December 31, 2026 | $-0.20 | +63.1% | $32M |
| Quarter after ends March 31, 2027 | $-0.46 | −2.7% | $4M |
Consensus of the analysts covering Monte Rosa Therapeutics, updated daily. In the last 30 days 2 estimates were raised and 1 lowered.
Frequently asked questions
What is the Monte Rosa Therapeutics stock price target?
The average 12-month target from 8 analysts is $25.38, 170.8% above the current price of $9.37 Targets range from $15.00 to $37.00.
Is Monte Rosa Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (2 strong buy, 8 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Monte Rosa Therapeutics expected to earn?
Analysts expect EPS of $-1.02 for the fiscal year ending December 31, 2026 and $-1.78 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.